Sarda Proteins Ltd Upgraded to Sell on Technical Improvement Despite Weak Fundamentals

Quality Assessment: Weak Fundamentals Persist

Despite the upgrade in rating, Sarda Proteins continues to exhibit weak fundamental quality. The company reported flat financial results for the quarter ended June 2026, with net sales for the nine months at a subdued ₹13.89 crores, reflecting a steep decline of 60.31% year-on-year. Operating losses remain a significant concern, with a negative EBITDA of ₹-2.49 crores and a PBDIT of ₹-3.27 crores for the quarter, underscoring ongoing operational challenges.

Profitability metrics remain underwhelming. The average Return on Equity (ROE) stands at a modest 8.81%, indicating limited profitability relative to shareholders’ funds. Furthermore, the company’s ability to service debt is weak, with an average EBIT to interest coverage ratio of -0.58, signalling financial strain and heightened risk for creditors and investors alike.

These factors contribute to the company’s low quality grade, which remains a key reason for caution despite the technical upgrade.

Valuation: Risky and Micro-Cap Status

Sarda Proteins is classified as a micro-cap stock, trading at ₹97.29 as of the latest close, up 5.00% from the previous day’s ₹92.66. The stock’s 52-week high is ₹144.30, while the low is ₹59.95, indicating significant price volatility over the past year. Despite this recent uptick, the stock’s valuation remains risky compared to its historical averages.

Over the last year, the stock has underperformed the broader market, generating a negative return of -29.04%, while the BSE500 index posted a modest gain of 0.64%. This underperformance, coupled with the company’s negative EBITDA and weak fundamentals, suggests that the stock is trading at a discount that reflects its operational and financial challenges.

Investors should note that while the stock has delivered strong long-term returns—131.64% over three years compared to the Sensex’s 13.48%—the recent trend has been less favourable, warranting a cautious approach to valuation.

Financial Trend: Flat Performance Amid Rising Promoter Confidence

The financial trend for Sarda Proteins remains largely flat, with no significant improvement in quarterly results. The company’s net sales have contracted sharply, and operating losses persist, reflecting ongoing challenges in the edible oil sector and company-specific issues.

However, a notable positive development is the rising promoter confidence. Promoters have increased their stake by 80.66% over the previous quarter, now holding 80.66% of the company’s equity. This substantial increase signals strong belief in the company’s future prospects from its controlling shareholders, which could provide stability and potential strategic support going forward.

Despite this, the weak financial metrics and negative EBITDA continue to weigh heavily on the company’s overall financial health and investor sentiment.

Technical Analysis: Shift to Mildly Bullish Trend Spurs Upgrade

The primary driver behind the upgrade from Strong Sell to Sell is the improvement in technical indicators. The technical trend has shifted from mildly bearish to mildly bullish, reflecting a more positive near-term outlook for the stock’s price movement.

Key technical signals include a bullish Moving Average Convergence Divergence (MACD) on the weekly chart, supported by bullish Bollinger Bands and daily moving averages. These indicators suggest increasing buying momentum and potential for price appreciation in the short term.

However, some mixed signals remain. The Relative Strength Index (RSI) on the weekly chart is bearish, and monthly MACD and Bollinger Bands remain mildly bearish, indicating that the longer-term trend is still uncertain. Other indicators such as the Know Sure Thing (KST) and Dow Theory readings are mildly bearish on both weekly and monthly timeframes, while On-Balance Volume (OBV) shows no clear trend.

Overall, the technical picture is cautiously optimistic, justifying the upgrade in rating but not yet signalling a strong buy opportunity.

Stock Price and Market Comparison

Sarda Proteins closed at ₹97.29, marking a 5.00% gain on the day. This contrasts favourably with the Sensex, which declined by 1.78% over the past week and 3.72% over the past month. Despite this short-term outperformance, the stock’s year-to-date return is not available, and it has significantly underperformed the market over the last year with a -29.04% return versus the Sensex’s -6.45%.

Longer-term returns remain impressive, with a 3-year return of 131.64% compared to the Sensex’s 13.48%, highlighting the stock’s potential for recovery if operational and financial issues are addressed.

Conclusion: Cautious Optimism Amidst Lingering Risks

The upgrade of Sarda Proteins Ltd’s investment rating from Strong Sell to Sell reflects a nuanced view of the company’s prospects. While technical indicators have improved, signalling a mildly bullish trend and short-term price momentum, the company’s fundamental and financial challenges remain significant.

Weak operating performance, negative EBITDA, poor debt servicing ability, and underwhelming profitability metrics continue to weigh on the stock’s quality and valuation. The micro-cap status and recent underperformance relative to the broader market add to the risk profile.

Nonetheless, the rising promoter stake signals confidence in the company’s future, which may provide some support. Investors should weigh the improved technical outlook against the persistent fundamental weaknesses and consider the stock’s risk profile carefully before making investment decisions.

Given these factors, the Sell rating is appropriate, reflecting cautious optimism but acknowledging the need for further improvement before a more positive outlook can be warranted.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today